Industry weighs radical shake-up of European drug pricing
Wholesale adoption of the concept of drug pricing based on clinical results is proposed
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
London
THE pharmaceutical industry is considering a radical shift in the way it prices drugs in Europe so companies are rewarded for the clinical benefit of treatments rather than the number of pills sold, according to an internal report.
The high price of drugs is straining Europe's cash-strapped health systems and depriving some patients of the latest products, to the concern of manufacturers who argue they can save costs in the long run by keeping people out of hospital.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
20 photos that show how dramatically Singapore has changed in two decades
Singapore’s key exports up 15.3% in March from electronics surge, exceeding forecasts
